A Dark Vector Cognition product

Moderna 10-Q 2026-09-30

MRNA · CIK 1682852 · Form 10-Q · Period ended September 30, 2026 · Filed November 6, 2026

Revenue rose 29.2% to $1.31 billion. Operating margin was 9.9%, against -25.6% a year earlier. Net income was $162 million.

8 sections, 204K characters. Original on sec.gov · ·

Risk FactorsBusiness

Key numbers
MeasureQuarter ended Sep 30, 2026Quarter ended Sep 30, 2025Change
Revenue$1.31B$1.02B+29.2%
Operating income$130M-$260Mn/a
Net income$162M-$200Mn/a
Diluted EPS$0.38-$0.51n/a
Cash and equivalents$1.20Bn/an/a
Operating margin*9.9%-25.6%+35.5 pts

From the XBRL facts tagged to this filing; both columns are as reported in this filing. * Computed by filings.tools: free cash flow is operating cash flow less capital spending; operating margin is operating income over revenue.

The 53 tables in this filing as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

Cover and table of contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2026

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _ to _

Commission File Number: 001-38753

modernalogoa04.jpg

Moderna, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware81-3467528
(State or Other Jurisdiction of Incorporation or Organization)(IRS Employer Identification No.)
325 Binney Street
Cambridge,Massachusetts02142
(Address of Principal Executive Offices)(Zip Code)

(617) 714-6500

(Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading symbol(s)Name of each exchange on which registered
Common stock, par value $0.0001 per shareMRNAThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer☒Accelerated filer oNon-accelerated filer oSmaller reporting company☐
Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

As of October 30, 2026, there were 404,620,975 shares of the registrant’s common stock, par value $0.0001 per share, outstanding.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q (Form 10-Q) contains express or implied forward-looking statements. All statements other than those of historical facts contained in this Form 10-Q are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements in this Form 10-Q include, but are not limited to, statements about:

  • our ability to drive use of our commercial products and expectations regarding sales growth in 2026;

  • our ability to execute on our prioritized research and development portfolio;

  • our ability to deliver cost efficiency across our business;

  • our expectations regarding the size and durability of the respiratory vaccine market;

  • our long-term strategic partnerships with government entities;

  • anticipated near-term regulatory actions for our product candidates, including potential filings, reviews and approvals;

  • anticipated milestones for our pipeline programs, including potential data readouts and other near-term catalysts;

  • our ability to obtain and maintain regulatory approval of our product candidates across our portfolio;

  • our ability to successfully launch and commercialize our products and the timing of launches;

  • the potential of intismeran and our oncology portfolio more broadly;

  • the progress of the clinical development program for intismeran and the potential of intismeran in other tumor types and across settings;

  • the favorable trend in overall survival data for intismeran;

  • encouraging activity observed in the Phase 1/2 study of mRNA-2808;

  • our ability and the ability of third parties with whom we contract to successfully manufacture, supply and distribute our commercial products and any future commercial products at scale, as well as drug substances, delivery vehicles, development candidates, and investigational medicines for preclinical and clinical use;

  • financing and funding options we may consider as part of our research and development strategy;

  • our ability to successfully contract with third-party suppliers, distributors and manufacturers;

  • internal and external costs associated with manufacturing our products and the impact on our cost of sales, and our anticipated cost of sales as a percentage of net product sales;

  • the scope of protection we are able to establish and maintain for intellectual property rights, including those covering our commercial products, product candidates and technology, and our expectations regarding pending legal proceedings related to our intellectual property;

  • the timing of initiation, progress, completion, results and cost of our clinical trials, preclinical studies and research and development programs, as well as those of our collaborators;

  • participant enrollment in our clinical trials, including timing;

  • potential advantages of mRNA as compared to traditional medicine;

  • the implementation of our business model and strategic plans for our business, products, product candidates and technology;

  • the pricing and reimbursement of our products, if approved;

  • the build out of our manufacturing and commercial operations;

  • estimates of our future expenses, revenues and capital requirements;

  • our operation and funding requirements, including our forecast of the period of time through which our financial resources will be adequate to support our operations;

  • the potential benefits of strategic collaboration agreements and our ability to enter into strategic collaborations or other agreements with collaborators with development, regulatory and commercialization expertise;

  • our financial performance;

  • our tax positions and related tax liabilities;

  • legal and regulatory developments in the United States and foreign countries;

  • the outcome of ongoing legal proceedings;

  • our ability to produce our products or product candidates with advantages in turnaround times or manufacturing cost; and

  • developments relating to our competitors and our industry.

Forward-looking statements often contain words such as “will,” “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our operational or financial performance, and involve risks, uncertainties, and other factors that may cause our actual results to differ materially from any future results expressed or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section entitled “Risk Factors” and elsewhere in this Form 10-Q and under Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual results could differ materially from those expressed or implied by the forward-looking statements.

The forward-looking statements in this Form 10-Q represent our views as of the date of this Form 10-Q. We undertake no obligation to update any forward-looking statements, except as required by applicable securities law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Form 10-Q. However, any further disclosures made on related subjects in our subsequent reports filed with the Securities and Exchange Commission should be consulted.

TRADEMARKS

This Form 10-Q contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to may appear without the ® or ™ symbols, but such references are not intended to indicate that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our reference to other companies’ trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

NOTE REGARDING COMPANY REFERENCES

Unless the context otherwise requires, the terms “Moderna,” the “Company,” “we,” “us” and “our” in this Form 10-Q refer to Moderna, Inc. and its consolidated subsidiaries.

ADDITIONAL INFORMATION

Our website, www.modernatx.com, including the Investor Relations section, www.investors.modernatx.com; and corporate blog www.modernatx.com/moderna-blog, and our Statements and Perspectives webpage, https://investors.modernatx.com/Statements--Perspectives/default.aspx; as well as our social media channels: Facebook, www.facebook.com/modernatx; X, www.x.com/moderna_tx (@moderna_tx); LinkedIn, www.linkedin.com/company/modernatx; Instagram (@moderna_tx); and Threads (@moderna_tx) contain a significant amount of information about us, including financial and other information for investors. We encourage investors to visit these websites and social media channels as information is frequently updated and new information is shared. Information contained on our website, corporate blog and social media channels shall not be deemed incorporated into, or be a part of, this Form 10-Q.

Table of Contents

PART I.Page
Item 1.Financial Statements (Unaudited)6
Condensed Consolidated Balance Sheets as of September 30, 2026 and December 31, 20256
Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2026 and 20257
Condensed Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended September 30, 2026 and 20258
Condensed Consolidated Statements of Stockholders' Equity for the three and nine months ended September 30, 2026 and 20259
Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2026 and 202511
Notes to Condensed Consolidated Financial Statements12
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations33
Item 3.Quantitative and Qualitative Disclosures about Market Risk43
Item 4.Controls and Procedures43
PART II.
Item 1.Legal Proceedings44
Item 1A.Risk Factors45
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds47
Item 5.Other Information47
Item 6.Exhibits48
SIGNATURES49

Item 1. Financial Statements

MODERNA, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited, in millions, except per share data)

September 30,December 31,
20262025
Assets
Current assets:
Cash and cash equivalents$1,195$2,595
Investments3,9763,204
Accounts receivable, net1,367184
Inventory313153
Prepaid expenses and other current assets493408
Total current assets7,3446,544
Investments, non-current2,8052,336
Property, plant and equipment, net2,0362,134
Right-of-use assets, operating leases687719
Other non-current assets596605
Total assets$13,468$12,338
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable$259$317
Accrued liabilities1,3951,386
Deferred revenue26899
Other current liabilities106185
Total current liabilities2,0281,987
Deferred revenue, non-current139153
Operating lease liabilities, non-current630653
Financing lease liabilities, non-current—20
Long-term debt591590
Convertible notes2,958—
Other non-current liabilities285285
Total liabilities6,6313,688
Commitments and contingencies (Note 12)
Stockholders’ equity:
Preferred stock, par value $0.0001; 162 shares authorized as of September 30, 2026 and December 31, 2025; no shares issued or outstanding at September 30, 2026 and December 31, 2025——
Common stock, par value $0.0001; 1,600 shares authorized as of September 30, 2026 and December 31, 2025; 404 and 394 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively——
Additional paid-in capital1,5691,382
Accumulated other comprehensive income845
Retained earnings5,2607,223
Total stockholders’ equity6,8378,650
Total liabilities and stockholders’ equity$13,468$12,338

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

MODERNA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited, in millions, except per share data)

Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Revenue:
Net product sales$1,273$973$1,719$1,172
Other revenue404312894
Total revenue1,3131,0161,8471,266
Operating expenses:
Cost of sales3182071,366416
Research and development5838011,8832,357
Selling, general and administrative282268671710
Total operating expenses1,1831,2763,9203,483
Income (loss) from operations130(260)(2,073)(2,217)
Interest income6273201244
Other (expense) income, net(21)—(58)4
Income (loss) before taxes171(187)(1,930)(1,969)
Provision for income taxes9133327
Net income (loss)$162$(200)$(1,963)$(1,996)
Earnings (loss) per share
Basic$0.40$(0.51)$(4.93)$(5.15)
Diluted$0.38$(0.51)$(4.93)$(5.15)
Weighted average common shares used in calculation of earnings (loss) per share
Basic401390398388
Diluted430390398388

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

MODERNA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(Unaudited, in millions)

Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Net income (loss)$162$(200)$(1,963)$(1,996)

Showing the first 8K of 162K characters. Open the full section

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Our market risks, and the way we manage them, are summarized in Part II, Item 7A., “Quantitative and Qualitative Disclosures About Market Risk” of our 2025 Form 10-K. There have been no material changes to our market risk or to our management of such risks for the three and nine months ended September 30, 2026.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2026. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s

management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September 30, 2026, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

Our management, including our Chief Executive Officer and Chief Financial Officer, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by the collusion of two or more people or by a management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

PART II

Item 1. Legal Proceedings

We are involved in various claims and legal proceedings of a nature considered ordinary course in our business, including those described under the heading “Legal Proceedings” in our 2025 Form 10-K and our Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2026 and June 30, 2026. Most of the issues raised by these claims are highly complex and subject to substantial uncertainties. For a description of risks relating to these and other legal proceedings we face, see Part I, Item 1A., “Risk Factors,” of our 2025 Form 10-K, including the discussion under the headings entitled “Risks related to our intellectual property” and “Risks related to the manufacturing of our commercial products and product candidates.” The outcome of any such proceedings, regardless of the merits, is inherently uncertain; therefore, assessing the likelihood of loss and any estimated damages is difficult and subject to considerable judgment.

GSK Patent Litigation

We and GSK Biologicals S.A. (GSK) entered into an agreement on October 28, 2026, to settle all disputes between the parties which were pending in the U.S. and Europe. Pursuant to the agreement, the parties granted patent cross-licenses in the field of infectious disease and are not obligated to make payments of any kind in connection with such licenses.

Pfizer/BioNTech Patent Litigation

As more fully described in our 2025 Form 10-K, we brought patent infringement actions against Pfizer Inc. (Pfizer), BioNTech SE (BioNTech) and related entities in Germany, the Netherlands, the UK, Ireland and Belgium concerning our mRNA platform technology and disease-specific vaccine designs. In September 2026, the Technical Board of Appeal of the European Patent Office revoked our European Patent No. 3 590 949 in all contracting states, including Germany, the Netherlands, the UK, Ireland and Belgium. Following this decision, the related national proceedings in Belgium, Ireland and the Netherlands have been dismissed. Proceedings in Germany and the UK remain pending awaiting the written decision of the Technical Board of Appeal.

In September 2026, we filed a complaint against Pfizer, BioNTech, and certain of their affiliates in the Hamburg Local Division of the Unified Patent Court (UPC) asserting our European Patent No. 3 981 437 to modified mRNA vaccines formulated in lipid nanoparticles. The complaint seeks a judgment of infringement of the asserted patent and unspecified damages.

CureVac Patent Litigation

In April 2026, CureVac Manufacturing GmbH filed a complaint against Moderna, Inc., ModernaTX, Inc., and certain of our affiliates in the Hague Local Division of the UPC asserting European Patent No. EP 4 108 769 related to mRNA production and purification methods. The complaint seeks a judgment of infringement of the asserted patent and unspecified damages.

In August 2026, CureVac SE filed a complaint against Moderna Biotech Spain S.L., Moderna Switzerland GmbH, Moderna Netherlands B.V., ModernaTX, Inc., Rovi Pharma Industrial Services S.A., and Recipharm Monts SAS in Commercial Court No. 5 of Barcelona, Spain, asserting European Patent No. 1 857 122 (EP’122) related to mRNA compositions with increased guanine and cytosine content. The complaint seeks a judgment of infringement of the asserted patent and unspecified damages.

In October 2026, CureVac SE filed a complaint against Moderna Switzerland GmbH, ModernaTX, Inc., Lonza AG, and Lonza Sales AG in the Swiss Federal Patent Court asserting EP’122 related to mRNA compositions with increased guanine and cytosine content. The complaint seeks a judgment of infringement of the asserted patent and unspecified damages.

Securities Class Action Litigation

As more fully described in our 2025 Form 10-K, in August 2024, a putative securities class action complaint was filed against Moderna and certain of its officers in the U.S. District Court for the District of Massachusetts. On October 8, 2026, the court issued a Memorandum & Order granting Moderna’s motion to dismiss. On October 13, 2026, the court entered an Order of Dismissal dismissing the action with prejudice. The decision is subject to appeal.

Item 1A. Risk Factors

Information regarding risk and uncertainties related to our business appears in Part I, Item 1A. “Risk Factors” of our 2025 Form 10-K. There have been no material changes from the risk factors previously disclosed in the 2025 Form 10-K other than set forth below.

Risks related to our convertible notes

Servicing our debt requires a significant amount of cash, and we may not have sufficient cash flow from our business to pay our substantial debt.

Our ability to make repayments of the principal of, to pay interest, if any, on or to refinance our indebtedness, including our outstanding 0.00% Convertible Senior Notes due 2032 (the notes), and to pay any cash amounts upon conversion of the notes, depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. Our business may not generate cash flow from operations in the future sufficient to service our debt and make necessary capital expenditures. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional debt or equity capital on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations.

We may not have the ability to raise the funds necessary to settle conversions of the notes in cash, to repay the notes at maturity or to repurchase the notes upon a fundamental change, and our future debt may contain limitations on our ability to pay cash upon conversion or repurchase of the notes.

Holders of the notes have the right, subject to certain conditions, to require us to repurchase all or any portion of their notes upon the occurrence of a fundamental change (as defined in the indenture governing the notes) at a fundamental change repurchase price equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid special interest, if any, to, but excluding, the fundamental change repurchase date. Upon maturity of the notes, we must pay the principal amount of the notes plus accrued and unpaid special interest, if any, in cash, unless the notes have been previously repurchased, redeemed or converted. In addition, upon conversion of the notes, unless we elect to issue solely shares of common stock to settle conversions (other than paying cash in lieu of delivering any fractional share), we will be required to make cash payments in respect of such conversions. However, we may not have enough available cash or be able to obtain financing upon maturity of the notes or at the time we are required to make repurchases of any notes surrendered therefor or pay cash with respect to notes being converted. In addition, our credit and guaranty agreement restricts, and our future debt may prohibit us from making any cash payments on the conversion or repurchase of the notes or making any cash payments upon a fundamental change. Our ability to repurchase the notes or to pay cash upon conversions or at maturity of the notes may also be limited by law or by regulatory authority. Our failure to repurchase notes at a time when the repurchase is required by the indenture governing the notes or to pay any cash payable on future conversions or at maturity of the

notes as required by the indenture governing the notes would constitute a default under the indenture governing the notes. A default under the indenture governing the notes or the fundamental change itself could also lead to a default under agreements governing our future indebtedness. If the repayment of the related indebtedness were to be accelerated after any applicable notice or grace periods, we may not have sufficient funds to repay the indebtedness and repurchase the notes or make cash payments upon conversions thereof.

The conditional conversion feature of the notes, if triggered, may adversely affect our financial condition and operating results.

In the event the conditional conversion feature of the notes is triggered, holders of notes will be entitled to convert their notes at any time during specified periods at their option. If one or more holders elect to convert their notes, unless we elect to satisfy our conversion obligation by delivering solely shares of common stock (other than paying cash in lieu of delivering any fractional share) we would be required to settle a portion or all of our conversion obligation through the payment of cash, which could adversely affect our liquidity. In addition, even if holders do not elect to convert their notes, we would be required under applicable accounting rules to reclassify all or any portion of the outstanding principal of the notes as a current rather than long-term liability, which would result in a material reduction of our net working capital.

Conversion of the notes may dilute the ownership interest of our stockholders or may otherwise depress the price of our common stock.

The conversion of some or all of the notes may dilute the ownership interests of our stockholders. Upon conversion of the notes, we have the option to pay or deliver, as the case may be, cash, shares of our common stock, or a combination of cash and shares of our common stock in respect of our conversion obligation. If we elect to settle our conversion obligation in shares of common stock or a combination of cash and shares of common stock, any sales in the public market of our common stock issuable upon such conversion could adversely affect prevailing market prices of our common stock. In addition, the existence of the notes may encourage short selling by market participants because the conversion of the notes could be used to satisfy short positions, or anticipated conversion of the notes into shares of our common stock could depress the price of our common stock.

The accounting method for the notes could adversely affect our reported financial condition and results.

The accounting method for reflecting the notes on our balance sheet, accruing interest expense for the notes and reflecting the underlying shares of our common stock in our reported diluted earnings per share may adversely affect our reported earnings and financial condition.

The notes are reflected as a liability on our balance sheets, with the initial carrying amount equal to the principal amount of the notes, net of issuance costs. The issuance costs were treated as a debt discount for accounting purposes, which is being amortized into interest expense over the term of the notes. As a result of this amortization, the interest expense that we expect to recognize for the notes for accounting purposes will be greater than the cash interest payments we will pay on the notes, which will result in lower reported net income or larger reported loss.

In addition, the shares of common stock underlying the notes are reflected in our diluted earnings per share using the “if converted” method. Under that method, diluted earnings per share is generally calculated assuming that all the notes were converted solely into shares of common stock at the beginning of the reporting period unless the result would be anti-dilutive. The application of the if-converted method may reduce our reported diluted earnings per share to the extent we are profitable in the future, and accounting standards may change in the future in a manner that may adversely affect our diluted earnings per share.

In addition, accounting standards may change in the future. Further, if in the future we irrevocably elect a settlement method to apply to conversions of notes, the accounting treatment for the notes could be different than described above. Accordingly, we may account for the notes in a manner that is significantly different than described above.

Certain provisions in the indenture governing the notes may delay or prevent an attempted takeover of us that might be financially advantageous to the shareholders.

Certain provisions in the indenture governing the notes may make it more difficult or expensive for a third party to acquire us. For example, the indenture governing the notes will require us, except as provided therein, to repurchase the notes for cash upon the occurrence of a fundamental change and, in certain circumstances, to increase the conversion rate for a holder that converts its notes in connection with a make-whole fundamental change. A takeover of us may trigger the requirement that we repurchase the notes and/or increase the conversion rate, which could make it costlier for a potential acquirer to engage in such takeover. Such additional costs may have the effect of delaying or preventing a takeover of us that would otherwise be beneficial to investors.

The capped call transactions may affect the market price of our common stock.

In connection with the offering of the notes, we entered into privately negotiated capped call transactions with certain financial institutions (the option counterparties). The capped call transactions cover, subject to customary adjustments, the number of shares of

our common stock that initially underlie the notes. The capped call transactions are expected generally to reduce the potential dilution to our common stock upon any conversion of notes and/or offset any cash payments we are required to make in excess of the principal amount of converted notes, as the case may be, with such reduction and/or offset subject to a cap.

We expect that the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to our common stock and/or purchasing or selling our common stock or other securities of ours in secondary market transactions prior to the maturity of the notes (and are likely to do so following any early conversion, repurchase, or redemption of the notes, to the extent we unwind a corresponding portion of the capped call transactions, or if we otherwise unwind all or a portion of the capped call transactions, and during the final observation period for the conversion of notes). This activity could also cause or avoid an increase or a decrease in the market price of our common stock.

The potential effect, if any, of these transactions and activities on the market price of the common stock will depend in part on market conditions. Any of these activities could adversely affect the value of the common stock.

We cannot predict the direction or magnitude of any potential effect that the transactions described above may have on the price of our common stock.

We are subject to counterparty risk with respect to the capped call transactions.

The option counterparties are financial institutions, and we are subject to the risk that one or more of the option counterparties may default or otherwise fail to perform, or may exercise certain rights to terminate, their obligations under the capped call transactions. Our exposure to the credit risk of the option counterparties is not secured by any collateral.

Global economic conditions have from time to time resulted in the actual or perceived failure or financial difficulties of many financial institutions and could adversely affect the option counterparties’ performance under the capped call transactions. If an option counterparty becomes subject to insolvency proceedings, we will become an unsecured creditor in those proceedings with a claim equal to our exposure at that time under the capped call transaction with such option counterparty. Our exposure will depend on many factors but, generally, our exposure will increase if the market price or the volatility of our common stock increases. In addition, upon a default or other failure to perform, or a termination of obligations, by an option counterparty, we may suffer more dilution than we currently anticipate with respect to our common stock.

In addition, the terms of the capped call transactions may be subject to adjustment, modification or, in some cases, renegotiation in the event of certain corporate and other transactions. The capped call transactions may not operate as we intend in the event that we are required to adjust the terms of such instruments as a result of transactions in the future or in the event of other unanticipated developments that may adversely affect the functioning of the capped call transactions.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Issuer Purchases of Equity Securities

On August 1, 2022, our Board of Directors authorized a share repurchase program for our common stock of up to $3.0 billion, with no expiration date. During the three months ended September 30, 2026, there were no shares repurchased. As of September 30, 2026, $1.7 billion of our Board of Directors’ authorization for repurchases of our common stock remains outstanding, with no expiration date.

For details about our share repurchase programs, please refer to Note 12 to our consolidated financial statements, as set forth in our 2025 Form 10-K.

Item 5. Other Information

None of our directors or officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934, as amended) adopted or terminated a "Rule 10b5-1 trading plan or arrangement" or a "non-Rule 10b5-1 trading plan or arrangement," as defined in Item 408(c) of Regulation S-K, during the fiscal quarter covered by this report.

Item 6. Exhibits

The Exhibits listed below are filed or incorporated by reference as part of this Form 10-Q.

Exhibit No.Exhibit Index
4.1Indenture, dated as of September 1, 2026, by and between Moderna, Inc. and U.S. Bank Trust Company, National Association, as Trustee (incorporated by reference to the Current Report on Form 8-K (File No. 001-38753) filed with the Securities and Exchange Commission on September 1, 2026)
4.2Form or Global Note, representing Moderna, Inc.’s 0.00% Convertible Senior Notes due 2032 (included as Exhibit A to the Indenture filed as Exhibit 4.1)
10.1Form of Confirmation for Capped Call Transactions (incorporated by reference to the Current Report on Form 8-K (File No. 001-38753) filed with the Securities and Exchange Commission on September 1, 2026)
31.1*Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1+Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*XBRL Instance Document - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH*XBRL Taxonomy Extension Schema Document
101.CAL*XBRL Taxonomy Extension Calculation Document
101.DEF*XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*XBRL Taxonomy Extension Label Linkbase Document
101.PRE*XBRL Taxonomy Extension Presentation Link Document
104*Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101.)
*Filed herewith
+The certification furnished in Exhibit 32.1 hereto is deemed to accompany this Form 10-Q and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certification will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.

SIGNATURES

Pursuant to the requirements of the Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MODERNA, INC.
Date:By:/s/ Stéphane Bancel
November 6, 2026
Stéphane Bancel
Chief Executive Officer and Director
(Principal Executive Officer)
Date:By:/s/ James M. Mock
November 6, 2026
James M. Mock
Chief Financial Officer
(Principal Financial Officer)